Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 10/20 | 0.62 |
| ▸ | SYK | P43405 | 3/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.48 |
| ▸ | IKBKB | O14920 | 1/20 | 0.46 |
| ▸ | CHUK | O15111 | 1/20 | 0.46 |
| ▸ | DCAF15 | Q66K64 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2819633 | 0.90 | ADORA2A (0.49) | ADORA2AADORA1KDM4EALDH1A1MAPT | |
| SCHEMBL2818884 | 0.89 | ADORA2A (0.64) | ADORA2ASYKADORA1IKBKBCHUK | |
| SCHEMBL2814644 | 0.86 | ADORA2A (0.60) | ADORA2AADORA1KDM4EALDH1A1MAPT | |
| SCHEMBL2818821 | 0.86 | KDM4E (0.47) | ADORA2AADORA1KDM4EALDH1A1LMNA | |
| SCHEMBL2820489 | 0.86 | ADORA2A (0.60) | ADORA2ASYKADORA1KDM4EALDH1A1 | |
| SCHEMBL2816602 | 0.86 | ADORA2A (0.60) | ADORA2ASYKADORA1KDM4EALDH1A1 | |
| SCHEMBL2815374 | 0.85 | ADORA2A (0.49) | ADORA2ASYKADORA1IKBKBCHUK | |
| SCHEMBL2820462 | 0.84 | ADORA2A (0.67) | ADORA2ASYKADORA1KDM4EALDH1A1 | |
| SCHEMBL2818045 | 0.83 | ADORA2A (0.62) | ADORA2AADORA1IKBKBCHUKKDM4E | |
| SCHEMBL2815826 | 0.83 | ADORA2A (0.62) | ADORA2AADORA1KDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2205602-B1 | IMIDAZO[1,2-A]QUINOXALINES AND DERIVATIVES THEREOF FOR TREATING CANCERS | UNIV MONTPELLIER (FR) | 2018-09-26 | — | — | EP | disclosed |
| US-8378098-B2 | Imidazol[1,2-α]quinoxalines and derivatives for the treatment of cancers | UNIVERSITE DE MONTPELLIER I (FR) | 2013-02-19 | — | — | US | disclosed |
| US-20100249142-A1 | IMIDAZOL[1,2-alpha]QUINOXALINES AND DERIVATIVES FOR THE TREATMENT OF CANCERS | UNIVERSITE DE MONTPELLIER I | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249142-A1 | IMIDAZOL[1,2-alpha]QUINOXALINES AND DERIVATIVES FOR THE TREATMENT OF CANCERS | IDH3A, NRAS, KRAS | ADORA2A 1818/4885SYK 2590/4885ADORA1 1985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.